A new peer-reviewed study found that regular use of ivermectin reduced the risk of dying from COVID-19 by 92%.
Paul Sacca
The large study was conducted by Flávio A. Cadegiani, MD, MSc, PhD. Cadegiani is a board-certified endocrinologist with a master's degree and doctorate degree in clinical endocrinology.
The peer-reviewed study was published on Wednesday by the online medical
journal Cureus. The study was conducted on a strictly controlled population of
88,012 people from the city of Itajaí in Brazil.
Individuals who used
ivermectin as prophylaxis or took the medication before being infected by COVID
experienced significant reductions in death and hospitalization.
According to the study, those
who took ivermectin regularly had a 92% reduction in their COVID death risk
compared to non-users and 84% less than irregular users.
"The hospitalization rate
was reduced by 100% in regular users compared to both irregular users and
non-users," the study stated.
The impressive reduction for regular ivermectin users was evident despite the regular users being at a higher risk for COVID deaths. The regular users were older and had a higher prevalence of type 2 diabetes and hypertension than irregular and non-users.
Irregular users of ivermectin
had a 37% lower mortality rate reduction than non-users.
The study defined regular
users as those who used more than 30 tablets of ivermectin over five months.
The dosage of ivermectin was determined by body weight, but "most of the
population used between two and three tablets daily for two days, every 15
days."
"Non-use of ivermectin
was associated with a 12.5-fold increase in mortality rate and a seven-fold
increased risk of dying from COVID-19 compared to the regular use of
ivermectin," the study read. "This dose-response efficacy reinforces
the prophylactic effects of ivermectin against COVID-19."
Cadegiani believes the study
showed a "dose-response effect" – which means that increasing levels
of ivermectin decreased the risk of hospitalization and death from COVID-19.
Cadegiani wrote on Twitter, "An observational study with the size and
level of analysis as ours is hardly achieved and infeasible to be conducted as
a randomised clinical trial. Conclusions are hard to be refuted. Data is data,
regardless of your beliefs."
Paul Sacca, The Blaze, 3-9-2022
ESSE REMÉDIO JUNTO COM ZINCO E CLOROQUINA DUROU 3 DIAS A COVID DE MINHA ESPOSA.
ResponderExcluir